Appeal No. 2003-1469 Page 2
Application No. 08/479,886
(a) a first mutation including an amino acid substitution in
a portion of said first ligand site selected from the
group consisting of (i) amino acid residue L15, R16,
R19 and Q22, (ii) the C-terminal 2/3 of the loop linking
helices 1 and 2, and (iii) the C-terminal ½ of helix 4;
and
(b) a second mutation in a portion of said second ligand
site selected from the group consisting of (i) the first
third of helix 1 and (ii) the middle half of helix 3.
65. A nucleic acid encoding a variant of a wild type
growth hormone having a first binding ligand site and
a second ligand binding site, said variant having non-
naturally occurring amino acid sequences comprising:
(a) a first mutation including an amino acid substitution in
a portion of said first ligand binding site selected from
the group consisting of:
(i) amino acid residue L15, R16, R19 and Q22;
(ii) amino acids 46-71; and
(iii) amino acids 169-184, and
(b) a second mutation including an amino acid
substitution in a portion of said second ligand binding
site selected from the group consisting of:
(i) amino acids 1-15; and
(ii) amino acids 106-128.
The examiner does not rely on any references.
Claims 49-52, 57-60, and 65-67 stand rejected under 35 U.S.C. § 112,
first paragraph, as nonenabled.
We reverse.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007